[-] Show simple item record

dc.contributor.authorGuthmann, Richardeng
dc.contributor.authorBahrami, Azitaeng
dc.contributor.authorMartin, Roberteng
dc.contributor.authorNashelsky, Joaneng
dc.date.issued2019eng
dc.descriptionIncludes bibliographical references||3 pageseng
dc.description.abstractQ Do A-fib patients continue to benefit from vitamin K antagonists with advancing age? Evidence-based answer: yes, patients with atrial fibrillation who are between the ages of 50 and 90 years continue to benefit from vitamin K antagonist therapy (warfarin) (strength of recommendation [SOR]: A, meta-analysis of randomized controlled trials [RCTs] and large cohorts). Regardless of age, warfarin produces a reduction in risk of thrombotic events that is 2- to 4-fold greater than the risk of hemorrhagic events.eng
dc.description.sponsorshipRichard Guthmann, MD, MPH; Azita Bahrami, DO; Robert Martin, DO, Advocate Illinois Masonic Family Medicine Residency, Chicago ; Joan Nashelsky, MLS, Family Physicians Inquiries Network, Columbia, Moeng
dc.identifier.citationJournal of Family Practice, vol. 68, no. 6 (July/August 2019), p. E12-E14eng
dc.identifier.urihttps://hdl.handle.net/10355/69682
dc.relation.ispartofseriesClinical inquiries;
dc.titleDo A-fib patients continue to benefit from vitamin K antagonists with advancing age?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record